Analysts Set STAAR Surgical (NASDAQ:STAA) Price Target at $45.57

Shares of STAAR Surgical (NASDAQ:STAA) have received a consensus rating of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $45.57.

Several analysts recently weighed in on the company. Stifel Nicolaus cut their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 26th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research note on Thursday, September 19th. BTIG Research lifted their price target on STAAR Surgical from $46.00 to $53.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Canaccord Genuity Group dropped their price target on shares of STAAR Surgical from $43.00 to $41.00 and set a “hold” rating on the stock in a research note on Thursday, August 8th. Finally, Morgan Stanley cut shares of STAAR Surgical from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $50.00 to $37.00 in a report on Monday, July 15th.

Insider Activity

In related news, Director Arthur C. Butcher bought 1,315 shares of the business’s stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $37.99 per share, with a total value of $49,956.85. Following the transaction, the director now owns 4,208 shares in the company, valued at approximately $159,861.92. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 1.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On STAAR Surgical

A number of large investors have recently made changes to their positions in STAA. Vanguard Group Inc. boosted its holdings in shares of STAAR Surgical by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,468,710 shares of the medical instruments supplier’s stock worth $170,678,000 after buying an additional 43,083 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of STAAR Surgical by 313.9% during the 1st quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 992 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of STAAR Surgical by 7.7% during the 1st quarter. Principal Financial Group Inc. now owns 302,669 shares of the medical instruments supplier’s stock valued at $11,586,000 after acquiring an additional 21,662 shares during the period. Perigon Wealth Management LLC increased its stake in shares of STAAR Surgical by 17.8% in the 1st quarter. Perigon Wealth Management LLC now owns 8,586 shares of the medical instruments supplier’s stock worth $329,000 after purchasing an additional 1,298 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of STAAR Surgical by 3.1% in the 1st quarter. BNP Paribas Financial Markets now owns 290,243 shares of the medical instruments supplier’s stock worth $11,111,000 after purchasing an additional 8,696 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors.

STAAR Surgical Stock Up 0.2 %

Shares of STAA stock opened at $30.39 on Wednesday. The business’s fifty day moving average is $32.45 and its 200 day moving average is $39.11. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of 98.03 and a beta of 0.59. STAAR Surgical has a twelve month low of $26.66 and a twelve month high of $52.68.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.09). STAAR Surgical had a return on equity of 5.60% and a net margin of 4.99%. The business had revenue of $99.01 million during the quarter, compared to the consensus estimate of $95.22 million. During the same quarter in the previous year, the business earned $0.23 earnings per share. The firm’s revenue was up 7.3% compared to the same quarter last year. Equities research analysts expect that STAAR Surgical will post 0.16 earnings per share for the current fiscal year.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.